SRF Ltd
SRF Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Chemicals business expected to grow 15% to 20% in FY27 despite pricing pressures and volatility. Chemicals business expected to grow 15%-20% in FY27 driven by strong product pipeline, technological interventions, and ramp-up of fluoropolymers and HFO capacities.
From SRF Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Chemicals business expected to grow 15% to 20% in FY27 despite pricing pressures and volatility.
- Strong product pipeline critical, spanning from intermediates through to AI and specialty chemicals.
- Fluoropolymer segment ramp-up anticipated in latter half of current year, with good revenue ramp expected in FY27.
- Chemours arrangement starting post-December FY26 (Q4), expected to yield high-margin outcomes.
- Exports of aluminum foil have commenced, with further growth expected through 2027.
- Incremental capacity enhancements underway at HFC segment, targeting over 65,000 MT per annum post-debottlenecking.
- New HFO portfolio capacity of 20,000 MT planned at Odisha site, with commissioning expected by February 2028.
2 more points management made on revenue & sales performance
Profitability & Margins
See what SRF Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR2,300 crore investment at Odisha over next 2 years for fourth-generation refrigerant gases capacity (20,000 MT/year) plus backward integration into hydrofluoric acid (30,000 MT), including electronic grade HF.
- Planned capex of approximately INR2,500 crore for FY27 aligned with long-term growth priorities.
- Successful start-up of capacitor-grade BOPP films plant (KAPLAR); to be capitalized shortly.
- BOPP & BOPE line expected to commence production in July FY27.
- Investment of INR180 crore in state-of-the-art BOPA (polyamide) line, expected operational by September 2027 (India’s first with simultaneous stretching).
- Pharma intermediates plant number 2 is coming up; on track at Dahej.
- Ongoing debottlenecking in chemicals to increase capacity north of 65,000 MT/year.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what SRF Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Q4 & FY26 earnings call transcript does not specifically disclose the current or expected orderbook/pending orders in quantified terms.
- It was mentioned that the company has very strong demand pull currently, meaning robust order inflows.
- There is ongoing fulfillment of demand, including exports, with no significant inventory stocking noted.
- The fluoropolymer segment and aluminum exports are ramping up, with good customer interest and approvals in progress.
- Upcoming projects, like the Chemours arrangement, are expected to contribute positively to order execution from Q4 FY26 and into FY27.
2 more points management made on order book & pipeline
SRF Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.6K Cr, net profit ₹582 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SRF Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
- Chemfab Alkalis Ltd (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…
- Sudarshan Pharma Industries Ltd (Q4 FY26)
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…
- Innovassynth Technologies (India) Ltd (Q4 FY26)
Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key concall takeaways from…
Frequently Asked Questions
What were SRF Ltd Q4 FY26 results?
Chemicals business expected to grow 15% to 20% in FY27 despite pricing pressures and volatility. Chemicals business expected to grow 15%-20% in FY27 driven by strong product pipeline, technological interventions, and ramp-up of fluoropolymers and HFO capacities.
What is SRF Ltd share price analysis?
SRF Ltd currently shows a neutral. The stock trades at a P/E of 33.2 with a market cap of ₹74,462 Cr. Investors should review the full earnings analysis for detailed insights.
Is SRF Ltd planning capital expenditure?
INR2,300 crore investment at Odisha over next 2 years for fourth-generation refrigerant gases capacity (20,000 MT/year) plus backward integration into hydrofluoric acid (30,000 MT), including electronic grade HF.
Keep SRF Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.